Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: A Phase IIa, randomized, double-blind, placebo-controlled study

Antiviral Therapy

Volumn 23, Issue 4, 2018, Pages 335-344

  Trevejo, Jose M ^a   Asmal, Mohammed ^b   Vingerhoets, Johan ^c   Polo, Ramon ^d   Robertson, Sarah ^e   Jiang, Ying ^f   Kieffer, Tara L ^e   Leopold, Lorant ^d  

^a VISTERRA INC   (United States)

^b BLUEBIRD BIO   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e VERTEX PHARMACEUTICALS   (United States)

^f ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INFLUENZA; INFLUENZA A VIRUS; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; VOLUNTEER; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD; VOLUNTEERS; YOUNG ADULT;

EID: 85053161710     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/imp3212     Document Type: Article

References (16)

1. WHO. Influenza virus infections in humans (February 2014). (Accessed 22 December 2016.) Available from http://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/influenza_virus_infections_ humans_feb14.pdf
2. Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol 2013; 4:293.
3. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 2013; 16:264-277.
4. Influenza Antiviral Medications CDC. Summary for clinicians. (Accessed 10 August 2015.) Available from http://www.cdc.gov/flu/professionals/antivirals/summaryclinicians.htm
5. van der Vries E, Schutten M, Fraaij P, et al. Influenza virus resistance to antiviral therapy. Adv Pharmacol 2013; 67:217-246.
6. Oseltamivir PI. (2016). (Accessed 22 December 2016.) Available from https://www.gene.com/download/pdf/tamiflu_prescribing.pdf
7. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children- diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
8. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 2013; 7 Suppl 1:25-36.
9. Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015; 59:1569-1582.
10. Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 2014; 57:6668-6678.
11. Kakuda T, Spittaels K, Vercauteren J, et al. Single- and multiple-dose pharmacokinetics of JNJ-63623872 and interaction with oseltamivir in healthy volunteers. XVII International Symposium on Respiratory Viral Infections. Vancouver, BC, Canada, 6-8 March 2015. Abstract P7.
12. Antachopoulos C, Margeli A, Giannaki M, Bakoula C, Liakopoulou T, Papassotiriou I. Transient hypophosphataemia associated with acute infectious disease in paediatric patients. Scand J Infect Dis 2002; 34:836-839.
13. Håglin L, Burman LA, Nilsson M. High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. J Intern Med 1999; 246:45-52.
14. Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respir Viruses 2012; 6:e2-e5.
15. Calfee DP, Peng AW, Hussey EK, et al. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999; 4:143-149.
16. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA 1999; 282:1240-1246.